Portfolio

enGene

CEO Jason Hanson

Development of gene therapy targeting mucosal tissues, including those of the bladder, lung and gut.

Gene delivery to mucosal tissues allows for the treatment of a wide range of diseases. enGene’s lead program is an immune-oncology gene therapy for treatment of non-muscle invasive bladder cancer, and has other programs in gene delivery to the lung and gut.

enGene is based in Montreal with management and clinical operations in Boston.

Human Health

Engene

CA

7171 Frederick-Banting
Montreal, Quebec
H4S 1Z9 Canada

Industry

Biotech

Status

Current

Location

Canada